ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma
Samuel D. Kaffenberger(Memorial Sloan Kettering Cancer Center), Peter E. Clark(Levine Cancer Institute), S. Duke Herrell(Vanderbilt University Medical Center), Daniel A. Barocas(Vanderbilt University Medical Center), Kelly Stratton(Oklahoma City University), Adu M. Boachie(Meharry Medical College), Sam S. Chang(Memorial Sloan Kettering Cancer Center), Todd M. Morgan(University of Michigan), Joseph A. Smith(King's College London), Michael S. Cookson(University of Oklahoma Health Sciences Center)
Cited by 55
Related Papers
The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
|New England Journal of Medicine|2003|2k
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
|The Journal of Urology|2007|1.1k
Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes
|The Journal of Urology|2007|845